Resveratrol inhibits glucose metabolism in human ovarian cancer cells

Gynecologic Oncology

Volumn 107, Issue 3, 2007, Pages 450-457

  Kueck, Angela ^a   Opipari Jr , Anthony W ^a   Griffith, Kent A ^b   Tan, Lijun ^a   Choi, Milheon ^a   Huang, Jennifer ^a   Wahl, Heather ^a   Liu, J Rebecca ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Akt; Autophagy; Glucose transport; Ovarian cancer; Resveratrol

Indexed keywords

AMINO ACID; CASPASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RESVERATROL; SULFORHODAMINE B;

ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG METABOLISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOPHAGY; CASPASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEOXYGLUCOSE; FEMALE; GLUCOSE; HUMANS; OVARIAN NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; STILBENES; TRITIUM;

EID: 36349001161     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.065     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
2. Fraser M., Leung B., Jahani-Asl A., Yan X., Thompson W.E., and Tsang B.K. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 1 (2003) 66
3. Vikhanskaya F., and Broggini M. Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. Int Rev Cytol 219 (2002) 157-198
4. Gadducci A., Cosio S., Muraca S., and Genazzani A.R. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol 23 (2002) 390-396
5. Coukos G., and Rubin S.C. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 91 (1998) 783-792
6. Jin S., DiPaola R.S., Mathew R., and White E. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 120 (2007) 379-383
7. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
8. Dang C.V., and Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem Sci 24 (1999) 68-72
9. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899
10. Bui T., and Thompson C.B. Cancer's sweet tooth. Cancer Cell 9 (2006) 419-420
11. Cantuaria G., Magalhaes A., Penalver M., Angioli R., Braunschweiger P., Gomez-Marin O., et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol 79 (2000) 33-37
12. Cantuaria G., Fagotti A., Ferrandina G., Magalhaes A., Nadji M., Angioli R., et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92 (2001) 1144-1150
13. Nanni C., Rubello D., Farsad M., De Iaco P., Sansovini M., Erba P., et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 31 (2005) 792-797
14. Zhu Z., Jiang W., McGinley J.N., and Thompson H.J. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res 65 (2005) 7023-7030
15. Michels K.B., and Ekbom A. Caloric restriction and incidence of breast cancer. JAMA 291 (2004) 1226-1230
16. Valenzano D.R., Terzibasi E., Genade T., Cattaneo A., Domenici L., and Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 16 (2006) 296-300
17. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5 (2006) 493-506
18. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 7117 (2006) 280-281
19. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 (1990) 1107-1112
20. Tai P.K., Liao J.F., Chen E.H., Dietz J., Schwartz J., and Carter-Su C. Differential regulation of two glucose transporters by chronic growth hormone treatment of cultured 3T3-F442A adipose cells. J Biol Chem 265 (1990) 21828-21834
21. Liu J.R., Opipari A.W., Tan L., Jiang Y., Zhang Y., Tang H., et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 62 (2002) 924-931
22. Gossner G., Choi M., Tan L., Fogoros S., Griffith K.A., Kuenker M., et al. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol 105 (2007) 23-30
23. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19 (2000) 5720-5728
24. Sexton E., Van Themsche C., LeBlanc K., Parent S., Lemoine P., and Asselin E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 5 (2006) 45
25. Feng Z., Zhang H., Levine A.J., and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102 (2005) 8204-8209
26. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., and Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377 (1995) 441-446
27. Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med 296 (1977) 486-492
28. Pelicano H., Martin D.S., Xu R.H., and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25 (2006) 4633-4646
29. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23 (2004) 5853-5857
30. Opipari Jr. A.W., Tan L., Boitano A.E., Sorenson D.R., Aurora A., and Liu J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 64 (2004) 696-703
31. Faber A.C., Dufort F.J., Blair D., Wagner D., Roberts M.F., and Chiles T.C. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol 72 (2006) 1246-1256
32. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J 397 (2006) 519-527
33. Jiang W., Zhu Z., and Thompson H.J. Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. Cancer Res 63 (2003) 1228-1234
34. Thompson H.J., McGinley J.N., Spoelstra N.S., Jiang W., Zhu Z., and Wolfe P. Effect of dietary energy restriction on vascular density during mammary carcinogenesis. Cancer Res 64 (2004) 5643-5650
35. Thompson H.J., Zhu Z., and Jiang W. Dietary energy restriction in breast cancer prevention. J Mammary Gland Biol Neoplasia 8 (2003) 133-142
36. Chang S.C., Ziegler R.G., Dunn B., Stolzenberg-Solomon R., Lacey Jr. J.V., Huang W.Y., et al. Association of energy intake and energy balance with postmenopausal breast cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 15 (2006) 334-341
37. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430 (2004) 686-689
38. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., and Walle U. Kristina high absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32 12 (2004) 1377-1382